|Article 1 (970.2 KB)||12 Pages||Available after Purchase|
|Article 2 (404.9 KB)||17 Pages||Available after Purchase|
|Article 3 (96.9 KB)||7 Pages||Available after Purchase|
|Article 4 (864.8 KB)||13 Pages||Available after Purchase|
|Article 5 (378 KB)||15 Pages||Available after Purchase|
|Article 6 (409.5 KB)||5 Pages||Available after Purchase|
|Transcript (78.1 KB)||19 Pages||Available after Purchase|
Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.
Financial: Dr. Michael Mithoefer has employment relationships with the Medical University of South Carolina and the Multidisciplinary Association for Psychedelic Studies. He has an ownership interest in Awakn Life Sciences and serves on the scientific advisory board. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.
Access never expires for this product.
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or email email@example.com.
Please wait ...